Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 295

• Price / Volume Information    Yesterday's Closing Price: $299.45 Daily Weekly Monthly 20 Day Moving Average: 316,855 shares Shares Outstanding: 29.48 (millions) Market Capitalization: $8,827.79 (millions) Beta: 0.50 52 Week High: $319.48 52 Week Low: $122.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.72% 6.26% 12 Week 8.36% 0.17% Year To Date 21.46% 13.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - investors@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer; President and Director Suma M. Krishnan - President Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Julian Gangolli - Director Peer Information Krystal Biotech, Inc. (CORR.) Krystal Biotech, Inc. (RSPI) Krystal Biotech, Inc. (CGXP) Krystal Biotech, Inc. (BGEN) Krystal Biotech, Inc. (GTBP) Krystal Biotech, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 29.48 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $8,827.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $1.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $7.98 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: 37.54 Trailing 12 Months: 40.03 PEG Ratio: - Price Ratios Price/Book: 6.91 Price/Cash Flow: 41.08 Price / Sales: 21.15 EPS Growth vs. Year Ago Period: 52.50% vs. Previous Quarter: 7.65% Sales Growth vs. Year Ago Period: 31.95% vs. Previous Quarter: 8.64% ROE 03/31/26 - 19.25 12/31/25 - 18.69 09/30/25 - 19.36 ROA 03/31/26 - 17.62 12/31/25 - 17.12 09/30/25 - 17.65 Current Ratio 03/31/26 - 9.46 12/31/25 - 9.95 09/30/25 - 10.14 Quick Ratio 03/31/26 - 9.06 12/31/25 - 9.56 09/30/25 - 9.73 Operating Margin 03/31/26 - 53.92 12/31/25 - 52.64 09/30/25 - 53.30 Net Margin 03/31/26 - 53.92 12/31/25 - 52.64 09/30/25 - 53.30 Pre-Tax Margin 03/31/26 - 49.68 12/31/25 - 48.69 09/30/25 - 50.10 Book Value 03/31/26 - 43.31 12/31/25 - 42.06 09/30/25 - 39.24 Inventory Turnover 03/31/26 - 0.64 12/31/25 - 0.66 09/30/25 - 0.68 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©